Homocysteine

Homocysteine is a sulfur-containing amino acid that sits at the crossroads of methylation, cardiovascular health, and B-vitamin status. It is produced as a transient intermediate during methionine metabolism and quickly recycled back to methionine (requiring B12 and folate) or shunted into transsulfuration (requiring B6). When any of those cofactors is insufficient, or when the MTHFR enzyme is genetically less efficient, homocysteine accumulates in the blood.

Optimal range

Range varies by individual.

Test frequency

Once at baseline; re-measure six to eight weeks after any methylation-targeted supplement protocol; annually as part of a comprehensive cardiovascular and cognitive risk panel if previously elevated.

When to measure

Measure at baseline if there is family history of premature cardiovascular disease, stroke, dementia, recurrent miscarriage, or known MTHFR variants. Anyone on a vegan or strict vegetarian diet should screen at intake because B12 insufficiency is common. Re-measure six to eight weeks after starting methylated B-vitamin supplementation to verify response. Persistent elevation despite cofactor repletion warrants workup for renal impairment or hypothyroidism.

How to measure

Serum total homocysteine, drawn fasted to minimize postprandial variability. Cost is $30–$80 retail; usually requires explicit request and is not part of a standard annual physical. LC-MS methods are preferred over older immunoassays for accuracy at lower values. Process the sample quickly (within one hour) or ensure plasma is separated promptly, since homocysteine continues to be released from red cells in the tube.

Why this biomarker matters

Elevated homocysteine has been linked across large cohorts to increased risk of cardiovascular events, stroke, cognitive decline, dementia, and adverse pregnancy outcomes. The strongest mechanistic evidence is for endothelial damage and pro-thrombotic effects at sustained values above 15 µmol/L. Whether lowering homocysteine pharmacologically reduces hard cardiovascular events has been controversial, large B-vitamin trials in established cardiovascular disease (HOPE-2, NORVIT) did not show event reduction, but cognitive-decline trials (VITACOG) and stroke prevention in specific subgroups have shown signal. For PrimalPrime purposes, homocysteine is most useful as a methylation-status readout. Optimal is under 8 µmol/L; values of 8–10 suggest suboptimal but acceptable status; above 10 warrants attention, and above 15 warrants intervention. The intervention is usually inexpensive: methylated folate (5-MTHF), methylcobalamin (B12), and pyridoxal-5-phosphate (B6) at moderate doses, alongside ensuring adequate choline and betaine intake from food.

The prime report

Weekly performance intelligence.

New studies, protocols, and optimization frameworks delivered every Monday. No fluff, no motivation quotes — only what moves the needle.